Prognostic factors in stage-i (T1N0) breast carcinoma patients: Who needs adjuvant systemic treatment?

Neoplasma

Volumn 54, Issue 4, 2007, Pages 353-358

  Yildirim, E ^a   Berberoglu, U ^a  

^a ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Adjuvant therapy; Breast carcinoma; Prognostic factors; Risk estimation; Stage 1

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CARCINOMA; CANCER STAGING; DISTANT METASTASIS; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; PROGNOSIS; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VOLUME; AGED; BREAST TUMOR; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 35448972124     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. GREENE FL, PAGE DL, FLEMING ID, et al, eds. AJCC Cancer Staging Manuel. 6th ed. New York,NY: Springer-Verlag; 2002.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
3. WESTENEND PJ, MEURS CJC, DAMHUIS RAM. Tumour size and vascular invasion predict distant metastasis in stage I breast cancer. Grade distinguishes early and late metastasis. J Clin Pathol 2005; 58: 196-201.
4. WOOD WC, MUSS HB, SOLIN LJ, OLOPADE OI. Malignant tumors of the breast. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles & Practice of oncology. Philadelphia: Lippincott Williams & Wilkins. 20005, 1415-1477.
5. HANRAHAN EO, VALERO V, GONZALES-ANGULO AM, HORTOBAGYI GN. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1:T1a,bN0M0): A review of the literature. J Clin Oncol 2006; 24: 2113-2122.
6. GOLDHIRSCH A, GLICK JH, GELBER RD, et al, and panel members. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583. (Pubitemid 41511089)
7. EIFEL P, AXELSON JA, COSTA J, et al. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93: 979-989, 2001.
8. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology, version 2.2006, Breast Cancer. http://www.nccn.org/professionals/ physician-gls/PDF/breast.pdf
9. KAPLAN EL, MEIER P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457-481
10. COX DR. Regression models and life tables. J R Stat Soc 1972; B34: 187-220.
11. KLEINBAUM DG, KUPPER LL, MULLER KE, et al, eds. Applied Regression Analysis and Other Multivariable Methods. Pacific Grove, CA: Brooks/Cole; 1998.
12. ROSEN PP, GROSHEN S, KINNE DW, NORTON L. Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 1993; 11: 2090-2100.
13. MIRZA AN, MIRZA NQ, VLASTOS G, SINGLETARY SE. Prognostic factors in node-negative breast cancer: A review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002; 235: 10-26.
14. JOENSUU H, PYLKKÄNEN L, TOIKKANNEN S. Late mortality from pT1N0M0 breast carcinoma. Cancer 1999; 85: 2183-2189.
15. JOENSUU H, ISOLA J, LUNDIN M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: A nationwide poipulation-based study. Clin Cancer Res 2003; 9: 923-930.
16. COLLEONI M, ROTMENSZ N, PERUZZOTTI G, et al. Minimal and small size invasive breast cancer with no axillary lymph node involvement: The need for tailored adjuvant therapies. Ann Oncol 2004; 15: 1633-1639.
17. ICHIZAWA N, FUKUTOMI T, IWAMOTO E, AKASHITANAKA S. Long-term results of T1a, T1b and T1c invasive breast carcinomas in Japanese women: Validation of the UICC T1 subgroup classification. Jpn J Clin Oncol 2002; 32: 108-109.
18. ARNESSON LG, SMEDS S, FAGERBERG G. Recurrence-free survival in patients with small breast cancers. Eur J Surg 1994: 160: 271-276.
19. FISHER B, DIGNAM J, TAN-CHIU E, et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 2001; 93: 112-120. (Pubitemid 32111988)
20. LEE AKC, DELELLIS RA, SILVERMAN ML, et al. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 1990; 8: 1457-1465.
21. LEE AKC, LODA M, MACKAREM G, et al. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bN0M0). Cancer 1997; 79: 761-771.
22. ROSNER D, LANE WW. Predicting recurrence in axillary-node negative breast cancer patients. Breast Cancer Res Treat 1993; 25: 127-139.
23. WOOD W, ANDERSON M, LYLES RH, et al. Can we select which patients with small breast cancers should receive adjuvant chemotherapy? Ann Surg 2002; 235: 859-862.